MedTrace Logo

Influence of Medication Taste on Pediatric Prescribers' Prescribing Habits

NCT01734759 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2013-10-21

No results posted yet for this study

Summary

The purpose of this study is to see if a medication taste test influences the prescribing habits of pediatric prescribers at Mayo Clinic.

Conditions

  • Healthy

Interventions

DRUG

Taste Test

Before the taste test each participant will fill out an informed consent form and an enrollment survey. Each participant will receive 0.5 mL of each study medication in the taste test. During the taste test each medication in a class will be labeled with a color name so as to prevent any bias from preconceived taste perception. They will record their perception of the medications taste on a visual analog scale (VAS). An anaphlyaxis kit will be on hand in case of emergencies. Between samples participants will cleanse their palate with a saltine cracker and 30 mL of water. 5 different classes of medications will be tested. Medications to be sampled and the corresponding dose of the test dose are: * Cephalosporins: cefdinir 12.5 mg, cefixime 10 mg * Penicillins: penicillin VK 12.5 mg, amoxicillin 12.5 mg * Analgesic/antipyretics: acetaminophen 16 mg, ibuprofen 10 mg * Steroids: prednisolone 1.5 mg, prednisone 0.5 mg * H2 receptor blockers: famotidine 4 mg, ranitidine 7.5 mg

Sponsors & Collaborators

Principal Investigators

  • Bernard Lee, PharmD, RPh · Mayo Clinic

  • Ole J Olson, Pharm.D., BCPS · Mayo Clinic

  • Michelle J LoTurco, Pharm.D. · Mayo Clinic

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01734759 on ClinicalTrials.gov